UroGen Pharma Ltd.
NASDAQ: URGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Elizabeth Barrett
- Employees
- 291
- Headquarters
- Princeton, United States
- IPO year
- 2017
- Market cap
- $1.7B
- Website
- https://www.urogen.com
Loading URGN…
Loading profile data…Frequently asked questions about URGN
What does UroGen Pharma Ltd. (URGN) do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-g...
Where does URGN trade?
UroGen Pharma Ltd. (URGN) trades on the NASDAQ.
What sector is URGN in?
UroGen Pharma Ltd. (URGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of UroGen Pharma Ltd.?
Elizabeth Barrett is the chief executive officer of UroGen Pharma Ltd. (URGN).
Where is UroGen Pharma Ltd. headquartered?
UroGen Pharma Ltd. is headquartered in United States.
Does URGN pay a dividend?
UroGen Pharma Ltd. (URGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did URGN go public?
UroGen Pharma Ltd. (URGN) completed its initial public offering in 2017.